Dharmaiah Srisathiyanarayanan, Bindu Lakshman, Tran Timothy H, Gillette William K, Frank Peter H, Ghirlando Rodolfo, Nissley Dwight V, Esposito Dominic, McCormick Frank, Stephen Andrew G, Simanshu Dhirendra K
NCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD 21701.
Laboratory of Molecular Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892.
Proc Natl Acad Sci U S A. 2016 Nov 1;113(44):E6766-E6775. doi: 10.1073/pnas.1615316113. Epub 2016 Oct 17.
Farnesylation and carboxymethylation of KRAS4b (Kirsten rat sarcoma isoform 4b) are essential for its interaction with the plasma membrane where KRAS-mediated signaling events occur. Phosphodiesterase-δ (PDEδ) binds to KRAS4b and plays an important role in targeting it to cellular membranes. We solved structures of human farnesylated-methylated KRAS4b in complex with PDEδ in two different crystal forms. In these structures, the interaction is driven by the C-terminal amino acids together with the farnesylated and methylated C185 of KRAS4b that binds tightly in the central hydrophobic pocket present in PDEδ. In crystal form II, we see the full-length structure of farnesylated-methylated KRAS4b, including the hypervariable region. Crystal form I reveals structural details of farnesylated-methylated KRAS4b binding to PDEδ, and crystal form II suggests the potential binding mode of geranylgeranylated-methylated KRAS4b to PDEδ. We identified a 5-aa-long sequence motif (Lys-Ser-Lys-Thr-Lys) in KRAS4b that may enable PDEδ to bind both forms of prenylated KRAS4b. Structure and sequence analysis of various prenylated proteins that have been previously tested for binding to PDEδ provides a rationale for why some prenylated proteins, such as KRAS4a, RalA, RalB, and Rac1, do not bind to PDEδ. Comparison of all four available structures of PDEδ complexed with various prenylated proteins/peptides shows the presence of additional interactions due to a larger protein-protein interaction interface in KRAS4b-PDEδ complex. This interface might be exploited for designing an inhibitor with minimal off-target effects.
KRAS4b( Kirsten大鼠肉瘤亚型4b)的法尼基化和羧甲基化对于其与质膜的相互作用至关重要,KRAS介导的信号转导事件在质膜上发生。磷酸二酯酶δ(PDEδ)与KRAS4b结合,并在将其靶向细胞膜中发挥重要作用。我们解析了人法尼基化-甲基化KRAS4b与PDEδ以两种不同晶体形式形成复合物的结构。在这些结构中,相互作用由C端氨基酸以及KRAS4b的法尼基化和甲基化的C185驱动,C185紧密结合在PDEδ中的中央疏水口袋中。在晶体形式II中,我们看到了法尼基化-甲基化KRAS4b的全长结构,包括高变区。晶体形式I揭示了法尼基化-甲基化KRAS4b与PDEδ结合的结构细节,晶体形式II表明了香叶基香叶基化-甲基化KRAS4b与PDEδ的潜在结合模式。我们在KRAS4b中鉴定出一个5个氨基酸长的序列基序(赖氨酸-丝氨酸-赖氨酸-苏氨酸-赖氨酸),该基序可能使PDEδ能够结合两种形式的异戊二烯化KRAS4b。对先前测试与PDEδ结合的各种异戊二烯化蛋白质的结构和序列分析,为一些异戊二烯化蛋白质(如KRAS4a、RalA、RalB和Rac)为何不与PDEδ结合提供了理论依据。将PDEδ与各种异戊二烯化蛋白质/肽复合的所有四个可用结构进行比较,结果表明,由于KRAS4b-PDEδ复合物中更大的蛋白质-蛋白质相互作用界面,存在额外的相互作用。这个界面可能被用于设计一种脱靶效应最小的抑制剂。